Archive · 1 Sep 2026
Sun Pharma Wins US Pricing Pact, Two-Year Tariff Reprieve
Sun Pharma made a medicine-pricing agreement with the United States government.
It promised to offer some medicines to state Medicaid programs at Most Favored Nation prices.
This means the prices would be linked to the lowest prices paid in certain other developed countries.
Sun Pharma also agreed to use this pricing approach for new innovative medicines.
In return, tariffs on some of its innovative medicines will be delayed for about two years.
Reports differ on whether the delay is exactly two years or longer.
The agreement’s other details have not been made public.
Sun Pharma is expanding its US business in areas such as skin care, cancer treatment, eye care and immunology.
The United States is a major market for the company and provides roughly 27% of its revenue.
Sun Pharma and its subsidiary Teva joined eight other drugmakers at a White House ceremony announcing US medicine-pricing agreements.
Sun Pharma will extend Most Favored Nation pricing to state Medicaid programs and future innovative or specialty medicine launches.
The agreement delays Section 232 tariffs on Sun Pharma’s innovative pharmaceutical products for two years or, according to another report, more than two years.
The nine participating companies committed to $19.6 billion in near-term US manufacturing investment, while other pact terms remain confidential.
The US generated about 27% of Sun Pharma’s June-quarter revenue, and its shares closed 0.3% higher at ₹1,925 before opening 0.69% lower in another report.
- Who
- Sun Pharmaceutical Industries, its subsidiary Teva, eight other drugmakers and the United States government.
- What
- They formalized agreements covering Most Favored Nation pricing, US manufacturing investment, ingredient reserves and delayed Section 232 tariffs.
- When
- The agreements were formalized on Monday; reports discussed Sun Pharma’s share performance on September 1.
- Where
- The agreements were announced at the White House and concern Sun Pharma’s US operations.
- Why
- The arrangement is intended to improve access to affordable medicines while recognizing participating companies’ investment in US manufacturing and operations.
Affordable-medicine and investment case
Tariff and pricing concerns
Purpose of the agreement
Affordable-medicine and investment case
The United States government and participating companies presented the agreements as a way to improve access to affordable medicines for US patients and encourage domestic manufacturing.
Tariff and pricing concerns
Analysts noted that companies are accepting MFN pricing commitments to reduce the risk and cost uncertainty associated with potential US tariffs on innovative medicines and imported pharmaceutical ingredients.
Effect on Sun Pharma
Affordable-medicine and investment case
The tariff delay gives Sun Pharma greater cost certainty for its high-margin specialty business and recognizes its investment in US research, sales and manufacturing.
Tariff and pricing concerns
The full commercial effect remains unclear because additional terms are confidential, while MFN pricing could affect pricing for Medicaid programs and future innovative products.
Tariff policy
Affordable-medicine and investment case
The Section 232 framework is intended to shift pharmaceutical manufacturing to the United States by making imports more expensive.
Tariff and pricing concerns
Indian drugmakers face the prospect of steep US tariffs, creating continued uncertainty for companies that manufacture or import medicines and ingredients for the US market.
- Pricing commitment
- Sun Pharma will apply Most Favored Nation pricing to state Medicaid programs and future innovative medicine launches.
- Tariff relief
- Section 232 tariffs on Sun Pharma’s innovative pharmaceutical products will be delayed for two years, although another report described the period as more than two years.
- Industry investment
- The nine participating drugmakers committed to $19.6 billion in near-term US manufacturing investment, according to a White House fact sheet.
- US revenue
- The United States accounted for about 27% of Sun Pharma’s June-quarter revenue; another report put the figure at 26.6% of consolidated sales in the first quarter of FY27.
- Organon acquisition
- Sun Pharma agreed to acquire Organon & Co. at an enterprise value of $11.75 billion.
- Ingredient reserves
- Sun Pharma also agreed to donate active pharmaceutical ingredients for key products to US government strategic reserves.
- Share performance
- Sun Pharma shares closed 0.3% higher at ₹1,925 in one report, while another reported a 0.69% decline at the September 1 market opening.
Sources
Sun Pharma secures over two-year relief from US pharma tariffs; pact signed with US govt to provide affordable drugs
Sun Pharma joins White House pricing pact: Agrees to MFN pricing for US Medicaid, gets 2-year tariff reprieve
